Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or intralipid for the treatment of AIDS-associated cryptococcal meningitis

Clinical Infectious Diseases

Volumn 23, Issue 3, 1996, Pages 556-562

  Joly, Véronique ^b   Aubry, Pierre ^b   Ndayiragide, Athanase ^b   Carrière, Isabelle ^b   Kawa, Emmanuel ^b   Mlika Cabanne, Najoua ^b   Aboulker, Jean Pierre ^b   Coulaud, Jean Pierre ^b   Larouze, Bernard ^b   Yeni, Patrick ^a  

^a BICHAT HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; GLUCOSE; INTRALIPID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CHILL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; FUNGAL MENINGITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL;

EID: 19244362836     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.3.556     Document Type: Article

References (24)

1. Powderly WG. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993;17:837-42.
2. Taelman H, Bogaerts J, Batungwanayo J, et al. Community-acquired bacteraemia, fungaemia and parasitaemia in febrile adults infected with HIV in Central Africa [abstract ThB526]. In: Program and abstracts of the 6th International Conference on AIDS (San Francisco). San Francisco: University of California, 1990.
3. Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989;321:794-9.
4. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326:83-9.
5. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Eng J Med 1992;326:793-8.
6. Dismukes WE. Management of cryptococcosis. Clin Infect Dis 1993;17(suppl 2):S507-12.
7. Armstrong D. Treatment of opportunistic fungal infections. Clin Infect Dis 1993;16:1-9.
8. Coker RJ, Viviani M, Gazzard BG, et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993;7:829-35.
9. Graybill JR, Sharkey PK, Vincent D, et al. Amphotericin B lipid complex (ABLC) in treatment (Rx) of cryptococcal meningitis (CM) in patients with AIDS [abstract 289]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 1991.
10. Moreau P, Milpied N, Fayette N, Ramée J-F, Harousseau J-L. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother 1992;30:535-41.
11. Caillot D, Casanovas O, Solary E, et al. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother 1993;31:161-9.
12. Joly V, Farinotti R, Saint-Julien L, Chéron M, Carbon C, Yeni P. In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid. Antimicrob Agents Chemother 1994;38:177-83.
13. July V, Geoffrey C, Reynes J, et al. Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients. J Antimicrob Chemother 1996 (in press).
14. British Society For Antimicrobial Chemotherapy Working Party. Antifungal chemotherapy in patients with acquired immunodeficiency syndrome. Lancet 1992;340:648-51.
15. Butler WT, Bennett JE, Alling DW, Wertlake PT, Utz JP, Hill GJ II. Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann Intern Med 1964;61:175-87.
16. Chavanet PY, Garry I, Charlier N, et al. Trial of glucose versus fat emulsion in preparation of amphotericin B for use in HIV-infected patients with candidiasis. BMJ 1992;305:921-5.
17. Rozenbaum R, Gonçalves AJR. Clinical epidemiological study of 171 eases of cryptococcosis. Clin Infect Dis 1994;18:369-80.
18. Chopra R, Fielding A, Goldstone AH. Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin (AmBisome) - a report on 40 cases from a single centre. Leuk Lymphoma 1992;7(suppl):73-7.
19. Proffitt RT, Satorius A, Chiang S-M, Sullivan L, Adler-Moore JP. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 1991;28(suppl B):49-61.
20. Clark JM, Whitney RR, Olsen SJ, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991;35:615-21.
21. Utz JP (moderator), Bennett JE, Brandriss MW, Butler WT, Hill GJ II (discussants). Amphotericin B toxicity: combined clinical staff conference at the National Institutes of Health. Ann Intern Med 1964;61:334-54.
22. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29.
23. Larsen RA, Leal MAE, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1990;113:183-7.
24. Van der Horst C, Saag M, Cloud G, et al. Part 1. Randomized double blind comparison of amphotericin B plus flucytosine (AMB + FC) to AMB alone (step 1) followed by a comparison of fluconazole to itraconazole (step 2) in the treatment of acute cryptococcal meningitis in patients with AIDS [abstract 1216]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.